|
1
|
Gilbar P, Hain A and Peereboom VM: Nail
toxicity induced by cancer chemotherapy. J Oncol Pharm Pract.
15:143–155. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Robert C, Soria JC, Spatz A, Le Cesne A,
Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V,
Armand JP and Le Chevalier T: Cutaneous side-effects of kinase
inhibitors and blocking antibodies. Lancet Oncol. 6:491–500. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tiseo M, Rossi G, Capelletti M, Sartori G,
Spiritelli E, Marchioni A, Bozzetti C, De Palma G, Lagrasta C,
Campanini N, Camisa R, Boni L, Franciosi V, Rindi G and Ardizzoni
A: Predictors of gefitinib outcomes in advanced non-small cell lung
cancer (NSCLC): study of a comprehensive panel of molecular
markers. Lung Cancer. 67:355–360. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Görn M, Habermann CR, Anige M, Thöm I,
Schuch G, Andritzky B, Brandl S, Burkholder I, Edler L, Hossfeld
DK, Bokemeyer C and Laack E: A pilot study of docetaxel and
trofosfamide as second-line ‘metronomic’ chemotherapy in the
treatment of metastatic non-small cell lung cancer (NSCLC).
Onkologie. 31:185–189. 2008.PubMed/NCBI
|
|
5
|
Young SD, Lafrenie RM and Clemons MJ:
Phase ii trial of a metronomic schedule of docetaxel and
capecitabine with concurrent celecoxib in patients with prior
anthracycline exposure for metastatic breast cancer. Curr Oncol.
19:75–83. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ladoire S, Eymard JC, Zanetta S, Mignot G,
Martin E, Kermarrec I, Mourey E, Michel F, Cormier L and
Ghiringhelli F: Metronomic oral cyclophosphamide prednisolone
chemotherapy is an effective treatment for metastatic
hormone-refractory prostate cancer after docetaxel failure.
Anticancer Res. 30:4317–4323. 2010.
|
|
7
|
Browder T, Butterfield CE, Kräling BM,
Marshall B, O’Reilly MS and Folkman J: Antiangiogenic scheduling of
chemotherapy improves efficacy against experimental drug-resistant
cancer. Cancer Res. 60:1878–1886. 2000.PubMed/NCBI
|
|
8
|
Bertolini F, Paul S, Mancuso P,
Monestiroli S, Gobbi A, Shaked Y and Kerbel RS: Maximum tolerable
dose and low-dose metronomic chemotherapy have opposite effects on
the mobilization and viability of circulating endothelial
progenitor cells. Cancer Res. 63:4342–4346. 2003.PubMed/NCBI
|
|
9
|
Man S, Bocci G, Francia G, Green SK, Jothy
S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G and Kerbel RS:
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide
administered continuously through the drinking water. Cancer Res.
62:2731–2735. 2002.PubMed/NCBI
|
|
10
|
Yokoi T, Tamaki T, Shimizu T and Nomura S:
A pilot study of a metronomic chemotherapy regimen with weekly
low-dose docetaxel for previously treated non-small cell lung
cancer. Lung Cancer: Targets and Therapy. 3:15–20. 2012.
|
|
11
|
Hong J, Park SH, Choi SJ, Lee SH, Lee KC,
Lee JI, Kyung SY, An CH, Lee SP, Park JW, Jeong SH, Nam E, Bang SM,
Cho EK, Shin DB and Lee JH: Nail toxicity after treatment with
docetaxel: a prospective analysis in patients with advanced
non-small cell lung cancer. Jpn J Clin Oncol. 37:424–428. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roh MR, Cho JY and Lew W:
Docetaxel-induced onycholysis: the role of subungual hemorrhage and
suppuration. Yonsei Med J. 48:124–126. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Correia O, Azevedo C, Pinto Ferreira E,
Braga Cruz F and Polónia J: Nail changes secondary to docetaxel
(Taxotere). Dermatology. 198:288–290. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sobin L and Wittekind CH: TNM
Classification of Malignant Tumours. 6th edition. Wiley-Liss; New
York: pp. 99–103. 2002
|
|
15
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar
|
|
16
|
National Cancer Institute (NCI): Common
Terminology Criteria for Adverse Events (CTCAE), version 4.0, 28
May 2009. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
Accessed October 9, 2012.
|
|
17
|
ten Bokkel Huinink WW, Prove AM, Piccart
M, Steward W, Tursz T, Wanders J, Franklin H, Clavel M, Verweij J,
Alakl M, Bayssas M and Kaye SB: A phase II trial with docetaxel
(Taxotere) in second line treatment with chemotherapy for advanced
breast cancer. A study of the EORTC Early Clinical Trials Group.
Ann Oncol. 5:527–532. 1994.PubMed/NCBI
|
|
18
|
Grover C, Reddy BS and Uma Chaturvedi K:
Diagnosis of nail psoriasis: importance of biopsy and
histopathology. Br J Dermatol. 153:1153–1158. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Scher RK, Tavakkol A, Sigurgeirsson B, Hay
RJ, Joseph WS, Tosti A, Fleckman P, Ghannoum M, Armstrong DG,
Markinson BC and Elewski BE: Onychomycosis: diagnosis and
definition of cure. J Am Acad Dermatol. 56:939–944. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Richert B, André J, Bourguignon R and de
la Brassinne M: Hyperkeratotic nail discoid lupus erythematosus
evolving towards systemic lupus erythematosus: therapeutic
difficulties. J Eur Acad Dermatol Venereol. 18:728–730. 2004.
View Article : Google Scholar
|
|
21
|
Stevenson R and El-Modir A: Unilateral
onycholysis in a patient taking erlotinib (Tarceva). BMJ Case Rep.
2011. View Article : Google Scholar
|
|
22
|
Truchuelo M, Vano-Galvan S, Pérez B,
Muñoz-Zato E and Jaén P: Unilateral taxane-induced onychopathy in a
patient with a brain metastasis. Dermatol Online J.
15:72009.PubMed/NCBI
|
|
23
|
Badger J, Banerjee AK and McFadden J:
Unilateral subungual hyperkeratosis following a cerebrovascular
incident in a patient with psoriasis. Clin Exp Dermatol.
17:454–455. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wasner G, Hilpert F, Schattschneider J,
Binder A, Pfisterer J and Baron R: Docetaxel-induced nail changes -
a neurogenic mechanism: a case report. J Neurooncol. 58:167–174.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fujiwara H, Hashikawa-Hobara N, Wake Y,
Takatori S, Goda M, Higuchi H, Zamami Y, Tangsucharit P and
Kawasaki H: Neurogenic vascular responses in male mouse mesenteric
vascular beds. J Pharmacol Sci. 119:260–270. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brain SD and Williams TJ: Inflammatory
oedema induced by synergism between calcitonin gene-related peptide
(CGRP) and mediators of increased vascular permeability. Br J
Pharmacol. 86:855–860. 1985. View Article : Google Scholar
|
|
27
|
Fazio R, Quattrini A, Bolognesi A,
Bordogna G, Villa E, Previtali S, Canal N and Nemni R: Docetaxel
neuropathy: a distal axonopathy. Acta Neuropathol. 98:651–653.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
New PZ, Jackson CE, Rinaldi D, Burris H
and Barohn RJ: Peripheral neuropathy secondary to docetaxel
(Taxotere). Neurology. 46:108–111. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Koskinen MJ, Kautio AL, Haanpää ML,
Haapasalo HK, Kellokumpu-Lehtinen PL, Saarto T and Hietaharju AJ:
Intraepidermal nerve fibre density in cancer patients receiving
adjuvant chemotherapy. Anticancer Res. 31:4413–4416.
2011.PubMed/NCBI
|
